Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00230607 · ClinicalTrials.gov registry record · Phase 4
Study of the Effects of Fabrazyme Treatment on Lactation and Infants
A Phase 4 study, sponsored by Genzyme, a Sanofi Company.
- Terminated
- Registry status
- Phase 4
- Development phase
- 7
- Enrollment target
NCT00230607 is a Phase 4 study that was terminated before completion, run by Genzyme, a Sanofi Company. The registered enrollment target is 7 participants.
The verdict
NCT00230607, a Phase 4 study, was terminated before completion, sponsored by Genzyme, a Sanofi Company.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 7 participants
- Enrollment target
Study Summary
The study was planned for up to 2 years (24 months). Planned full participation for both mother and infant was 24 months, planned full participation of mother and development of infant was 24 months, while planned full participation of mother and no infant participation was 6 months.
Interventions
- DRUG agalsidase beta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2006-05-28 |
| Est. Completion | 2024-02-09 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00230607
The ClinicalTrials.gov registry entry for NCT00230607 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 7 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Genzyme, a Sanofi Company, which has 196 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which agalsidase beta is the first listed.
NCT00230607 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00230607 about?
NCT00230607 is a clinical study titled "Study of the Effects of Fabrazyme Treatment on Lactation and Infants". The study was planned for up to 2 years (24 months). Planned full participation for both mother and infant was 24 months, planned full participation of mother and development of infant was 24 months, while planned full participation of mother and no infant participation was 6 months.
What is the current status of trial NCT00230607?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 7 participants. The study started on 2006-05-28. Estimated completion is 2024-02-09.
What interventions are being tested in trial NCT00230607?
The interventions under investigation include: agalsidase beta (DRUG).
Who is sponsoring clinical trial NCT00230607?
This trial is sponsored by Genzyme, a Sanofi Company, which has 196 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.